Cooper Companies (COO)
Market Price (12/26/2025): $82.57 | Market Cap: $16.3 BilSector: Health Care | Industry: Health Care Supplies
Cooper Companies (COO)
Market Price (12/26/2025): $82.57Market Cap: $16.3 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% | Weak multi-year price returns2Y Excs Rtn is -56%, 3Y Excs Rtn is -77% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 24x, P/EPrice/Earnings or Price/(Net Income) is 44x |
| Low stock price volatilityVol 12M is 36% | Key risksCOO key risks include [1] challenges from its extensive international operations, Show more. | |
| Megatrend and thematic driversMegatrends include Precision Medicine, Biotechnology & Genomics, and Health & Wellness Innovations. Themes include Personalized Diagnostics, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Low stock price volatilityVol 12M is 36% |
| Megatrend and thematic driversMegatrends include Precision Medicine, Biotechnology & Genomics, and Health & Wellness Innovations. Themes include Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -56%, 3Y Excs Rtn is -77% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 24x, P/EPrice/Earnings or Price/(Net Income) is 44x |
| Key risksCOO key risks include [1] challenges from its extensive international operations, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Here are five key points explaining the approximate 22.5% stock movement for Cooper Companies (COO) from August 31, 2025, to December 26, 2025:1. Strong Fiscal Fourth Quarter and Full Year 2025 Financial Results: On December 4, 2025, CooperCompanies announced robust financial performance for its fiscal fourth quarter and full year ended October 31, 2025. The company reported a non-GAAP diluted earnings per share (EPS) of $1.15 for Q4 2025, an 11% increase, and $4.13 for the full fiscal year, up 12%, both exceeding analysts' consensus estimates. Additionally, Q4 revenue reached $1,065.2 million, up 5% (3% organically), with full fiscal year revenue at $4.1 billion, also up 5% (4% organically). These positive results led to a favorable market reaction.
2. Appointment of Key Independent Director and Cooperation Agreement with Activist Investor: CooperCompanies announced on December 23, 2025, the appointment of Walter (Walt) M. Rosebrough, Jr. as an independent director, effective January 3, 2026. This appointment was made in connection with a cooperation agreement with Browning West, LP, an activist investment firm that had advocated for changes at the board level. Rosebrough, a former CEO of STERIS plc, brings extensive medical device industry experience, and the board committed to considering him for the role of Board Chair by the end of 2026, signaling enhanced strategic direction and governance.
Show more
Stock Movement Drivers
Fundamental Drivers
The 23.4% change in COO stock from 9/25/2025 to 12/25/2025 was primarily driven by a 33.1% change in the company's P/E Multiple.| 9252025 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 66.89 | 82.57 | 23.44% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 4045.70 | 4092.40 | 1.15% |
| Net Income Margin (%) | 10.08% | 9.16% | -9.12% |
| P/E Multiple | 32.69 | 43.52 | 33.13% |
| Shares Outstanding (Mil) | 199.30 | 197.60 | 0.85% |
| Cumulative Contribution | 23.43% |
Market Drivers
9/25/2025 to 12/25/2025| Return | Correlation | |
|---|---|---|
| COO | 23.4% | |
| Market (SPY) | 4.9% | 27.2% |
| Sector (XLV) | 16.2% | 42.2% |
Fundamental Drivers
The 18.5% change in COO stock from 6/26/2025 to 12/25/2025 was primarily driven by a 29.4% change in the company's P/E Multiple.| 6262025 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 69.69 | 82.57 | 18.48% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3988.20 | 4092.40 | 2.61% |
| Net Income Margin (%) | 10.39% | 9.16% | -11.79% |
| P/E Multiple | 33.63 | 43.52 | 29.40% |
| Shares Outstanding (Mil) | 199.90 | 197.60 | 1.15% |
| Cumulative Contribution | 18.47% |
Market Drivers
6/26/2025 to 12/25/2025| Return | Correlation | |
|---|---|---|
| COO | 18.5% | |
| Market (SPY) | 13.1% | 23.6% |
| Sector (XLV) | 16.6% | 42.1% |
Fundamental Drivers
The -11.0% change in COO stock from 12/25/2024 to 12/25/2025 was primarily driven by a -9.0% change in the company's Net Income Margin (%).| 12252024 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 92.81 | 82.57 | -11.03% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3895.40 | 4092.40 | 5.06% |
| Net Income Margin (%) | 10.07% | 9.16% | -9.04% |
| P/E Multiple | 47.13 | 43.52 | -7.65% |
| Shares Outstanding (Mil) | 199.20 | 197.60 | 0.80% |
| Cumulative Contribution | -11.04% |
Market Drivers
12/25/2024 to 12/25/2025| Return | Correlation | |
|---|---|---|
| COO | -11.0% | |
| Market (SPY) | 15.8% | 42.2% |
| Sector (XLV) | 13.3% | 48.6% |
Fundamental Drivers
The -0.7% change in COO stock from 12/26/2022 to 12/25/2025 was primarily driven by a -21.5% change in the company's Net Income Margin (%).| 12262022 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 83.17 | 82.57 | -0.72% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3308.50 | 4092.40 | 23.69% |
| Net Income Margin (%) | 11.66% | 9.16% | -21.46% |
| P/E Multiple | 42.67 | 43.52 | 1.99% |
| Shares Outstanding (Mil) | 198.00 | 197.60 | 0.20% |
| Cumulative Contribution | -0.72% |
Market Drivers
12/26/2023 to 12/25/2025| Return | Correlation | |
|---|---|---|
| COO | -12.4% | |
| Market (SPY) | 48.3% | 38.0% |
| Sector (XLV) | 18.5% | 47.5% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| COO Return | 13% | 15% | -21% | 14% | -3% | -10% | 3% |
| Peers Return | � | � | � | 6% | 11% | 15% | � |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 115% |
Monthly Win Rates [3] | |||||||
| COO Win Rate | 58% | 67% | 50% | 58% | 50% | 50% | |
| Peers Win Rate | � | � | 53% | 50% | 53% | 63% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| COO Max Drawdown | -24% | -2% | -41% | -7% | -10% | -30% | |
| Peers Max Drawdown | � | � | � | -9% | -7% | -14% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: JNJ, HOLX, BSX, BLCO, MDT. See COO Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)
How Low Can It Go
| Event | COO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -45.5% | -25.4% |
| % Gain to Breakeven | 83.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -32.4% | -33.9% |
| % Gain to Breakeven | 47.9% | 51.3% |
| Time to Breakeven | 203 days | 148 days |
| 2018 Correction | ||
| % Loss | -17.7% | -19.8% |
| % Gain to Breakeven | 21.4% | 24.7% |
| Time to Breakeven | 85 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -80.3% | -56.8% |
| % Gain to Breakeven | 408.0% | 131.3% |
| Time to Breakeven | 748 days | 1,480 days |
Compare to JNJ, BSX, REGN, BHC, STAA
In The Past
Cooper Companies's stock fell -45.5% during the 2022 Inflation Shock from a high on 9/3/2021. A -45.5% loss requires a 83.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
AI Analysis | Feedback
- Like Johnson & Johnson for contact lenses.
- Like Hologic for women's healthcare and fertility products.
AI Analysis | Feedback
- Contact Lenses: Manufactures and markets a comprehensive range of soft contact lenses, including daily disposable, two-week, and monthly lenses, for various vision corrections like spherical, astigmatic, and presbyopic.
- Women's Healthcare Devices & Services: Provides a diverse portfolio of medical devices, diagnostic products, and fertility solutions primarily focused on reproductive health, obstetrics, and gynecology.
AI Analysis | Feedback
Cooper Companies (symbol: COO) primarily sells its products to other companies rather than directly to individual consumers. Due to the highly fragmented nature of the global eye care and women's healthcare markets, Cooper Companies does not have a few "major customer companies" that individually account for a significant portion of its revenue, nor are such customers publicly disclosed in its financial filings.
Instead, Cooper Companies distributes its products through a broad network of businesses. Its primary customer categories include:
- Eye Care Professionals and Retailers (for CooperVision products): These customers include independent optometry and ophthalmology practices, large optical retail chains (e.g., Pearle Vision, LensCrafters, which are part of larger parent companies like EssilorLuxottica, symbol: EL), and distributors that supply these practices and retailers with contact lenses.
- Healthcare Institutions and Professionals (for CooperSurgical products): This category encompasses hospitals, fertility clinics, obstetrics and gynecology (OB/GYN) practices, surgical centers, and diagnostic laboratories. These entities purchase CooperSurgical's medical devices, diagnostic products, and surgical instruments.
- Medical Device and Pharmaceutical Distributors: Companies that specialize in the distribution of medical products to a wide range of healthcare providers, particularly in regions where Cooper may leverage indirect sales channels.
While specific publicly traded companies accounting for a significant portion of Cooper Companies' revenue are not disclosed, the above categories represent the types of businesses that are direct customers of Cooper Companies.
AI Analysis | Feedback
nullAI Analysis | Feedback
Albert G. White III, President & Chief Executive Officer
Mr. White has served as President, Director, and Chief Executive Officer of The Cooper Companies since May 2018. His previous roles at Cooper include Chief Financial Officer (2016-2018), Chief Executive Officer of Cooper Medical Inc. (2015-2018), Executive Vice President and Chief Strategy Officer (2011-2015), Vice President, Investor Relations (2007-2013), and Vice President and Treasurer (2006-2012). Prior to joining Cooper, he was a Director with KeyBanc Capital Markets for three years and held various leadership positions within KeyBank National Association for eight years. He also currently serves as a board member of Evolus Inc. No information indicates that Mr. White founded other companies, sold companies he was previously involved with to an acquirer, or has a pattern of managing companies directly backed by private equity firms; however, his background in investment banking would involve interactions with such firms and transactions.
Brian G. Andrews, Executive Vice President, Chief Financial Officer & Treasurer
Mr. Andrews has served as Executive Vice President, Chief Financial Officer, and Treasurer of The Cooper Companies since December 2020. His prior roles at Cooper include Senior Vice President (since 2018), Treasurer (since 2013), Vice President (since 2014), and Vice President, Global Logistics and Service for CooperSurgical (2017-2018). Before joining Cooper, he held various corporate and investment banking positions at KeyBanc Capital Markets (2002-2006) and ING Barings (2000-2001). No information indicates that Mr. Andrews founded or managed other companies, sold companies he was previously involved with to an acquirer, or has a pattern of managing companies directly backed by private equity firms; however, his investment banking background suggests experience with financial transactions including those with private equity.
Daniel G. McBride, Executive Vice President & Chief Operating Officer
Mr. McBride has been the Executive Vice President and Chief Operating Officer of The Cooper Companies since November 2013. He also served as President of CooperVision from February 2014 through January 2022. His previous roles at Cooper include Chief Risk Officer (2011-2013), General Counsel (2007-2014), and Vice President (2006-2013). Before joining Cooper in 2005, Mr. McBride was an attorney with Latham & Watkins LLP, where he focused on mergers and acquisitions and corporate finance matters.
Holly R. Sheffield, President, CooperSurgical
Ms. Sheffield has served as President of CooperSurgical, Inc. since July 2020. She joined CooperCompanies in June 2018 as Executive Vice President & Chief Strategy Officer. Prior to Cooper, she accumulated over 20 years of experience in investment banking, including serving as Managing Director, Global Head of Medical Technology at UBS Securities (2009-2018), and as a Managing Director in Healthcare Banking at Credit Suisse (2000-2009). She began her career at Donaldson, Lufkin & Jenrette (1997-2000) before its acquisition by Credit Suisse.
Jerry Warner, President, CooperVision
Mr. Warner has served as President of CooperVision, Inc. since February 2022. He previously held the titles of Executive Vice President, Americas & Global Commercial Functions of CooperVision (2019-2022) and President, Americas (2015-2019). Prior to joining CooperVision in 2012, Mr. Warner spent 17 years at Bausch + Lomb in various marketing and management roles.
AI Analysis | Feedback
The Cooper Companies (COO) faces several key risks to its business, primarily stemming from global economic conditions, the complexities of international operations, and a dynamic regulatory landscape. The most significant risk involves **market and economic volatility, coupled with international operational challenges**. The company is exposed to substantial risks due to current market conditions, including recessionary pressures, inflation, and economic volatility, which could hinder its growth. Its extensive international operations further expose it to uncertainties such as currency fluctuations, diverse regulatory hurdles, and geopolitical tensions. This can impact liquidity and financial condition, as well as complicate business objectives globally. Another key risk stems from **regulatory and compliance pressures**. Cooper Companies must navigate a complex web of economic and trade sanctions, tariffs, and import/export regulations, which could increase operational costs and complexity. Specific regulatory changes, such as the European Union's Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), have led to industry-wide cost adjustments, impacting margins and supply chains. Additionally, the company faces pricing pressure from competitors and changes in third-party coverage and reimbursement, which can affect demand for its products. Finally, **supply chain and operational disruptions** pose a significant threat. Cooper Companies relies on independent suppliers and third-party logistics providers, making it vulnerable to disruptions that could lead to inventory shortages. The company also faces operational risks related to potential interruptions in manufacturing, distribution, and storage. Furthermore, increasing cybersecurity threats present risks of data breaches and operational disruptions, and the implementation of new enterprise resource planning systems could lead to increased costs and potential service interruptions.AI Analysis | Feedback
- Shift in the reproductive healthcare landscape due to evolving regulations, particularly in the United States. Changes following the overturning of Roe v. Wade are leading to varying state-level restrictions on abortion access, which could reduce the market demand for certain gynecological and obstetric instruments and consumables provided by CooperSurgical.
- Increasing adoption of non-invasive prenatal testing (NIPT) which reduces the demand for products used in more invasive diagnostic procedures such as amniocentesis and chorionic villus sampling (CVS). As NIPT technology becomes more accurate and widespread, it poses a threat to CooperSurgical's traditional line of obstetric instruments and devices used for these invasive procedures.
AI Analysis | Feedback
The Cooper Companies (COO) operates primarily through two segments: CooperVision and CooperSurgical.CooperVision (Contact Lenses)
The global addressable market for contact lenses was estimated at USD 18.6 billion in 2023 and is projected to reach USD 33.8 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 8.9% from 2024 to 2030. North America accounted for the largest share of this market, holding over 38% in 2023. CooperVision is the third-largest manufacturer of soft contact lenses, holding approximately 17% of the global market share. In the U.S., Cooper controls roughly one fourth of the contact lens market.CooperSurgical (Women's Health and Fertility)
This segment addresses two main markets: women's health and fertility services.Women's Health Market
The global women's health market size was estimated at USD 49.33 billion in 2024 and is projected to reach USD 68.53 billion by 2030, with a CAGR of 5.1% from 2025 to 2030. North America dominated the global market with a share of 43.04% in 2024. The U.S. accounted for 87.70% of the total market share in North America in 2024.Fertility Services Market
The global fertility services market size is valued at USD 45.33 billion in 2025 and is estimated to reach USD 79.28 billion by 2034, growing at a CAGR of 6.45% during the forecast period. Europe dominated the market with a revenue share of 34.86% in 2025.AI Analysis | Feedback
The Cooper Companies (COO) is expected to drive future revenue growth over the next 2-3 years through several key strategies and market trends:- Growth in Myopia Management: CooperVision's MiSight and other myopia management products are anticipated to be significant drivers of future revenue. The increasing global prevalence of myopia is creating substantial demand for vision correction solutions, with MiSight sales projected to grow considerably in the coming years. For example, MiSight revenue is expected to increase by 20% by year-end 2025 and 40% for the full year 2025.
- Continued Adoption of Daily Silicone Hydrogel Contact Lenses: The ongoing shift towards daily disposable contact lenses, particularly within the silicone hydrogel category, is a strong growth catalyst. Products like MyDay and clariti are key contributors, with CooperVision benefiting from strong demand, accelerating fitting activity, and improved manufacturing capacity for these popular offerings. The company expects to remain a leader through innovation and a robust product portfolio in this segment.
- Strength in Toric and Multifocal Contact Lens Segments: CooperVision has effectively captured growth in the toric and multifocal contact lens markets, which represent a substantial portion of its overall revenue. The focus on providing mid-end and high-end contact lenses to correct near- and farsightedness in these specialized categories is expected to continue contributing to revenue expansion.
- Expansion of the Fertility Business within CooperSurgical: CooperSurgical's fertility business is a consistent driver of organic growth, offering a market-leading portfolio of innovative products and services. This includes consumables, capital equipment, reproductive genetic testing, and donor services, all addressing the long-term growth potential of the global fertility market. CooperSurgical is forecasted to achieve organic growth of 3.5% to 4.5% in 2025.
- Strategic Price Increases and Sustained Market Share Gains: Cooper Companies has demonstrated pricing power, particularly within its vision business, enabling it to implement price increases that offset cost inflation and generate additional gross profits. Concurrently, CooperVision continues to achieve market share gains in the competitive contact lens market, further bolstering its revenue trajectory. The company aims to grow faster than the overall contact lens market.
AI Analysis | Feedback
Share Repurchases
- Cooper Companies' Board of Directors approved a $1 billion increase to its share repurchase program in September 2025, bringing the total authorization to $2 billion.
- The company repurchased $52.2 million of its common stock (0.7 million shares) in Q3 fiscal year 2025.
- For the nine months ended July 31, 2025, Cooper Companies repurchased 1.2 million shares for $92.8 million, with $163.6 million remaining under the authorized program.
Share Issuance
- Specific dollar amounts of shares issued were not readily available; however, shares outstanding saw minor fluctuations.
- Cooper's shares outstanding increased by 0.55% in fiscal year 2024 to 0.2 billion from 2023, and by 0.25% in fiscal year 2023 to 0.199 billion from 2022.
- Shares outstanding saw a slight decline of 0.2% in fiscal year 2022 from 2021.
Outbound Investments
- In November 2021, Cooper Companies acquired Generate, a stem cell storage services provider, for $1.6 billion.
- CooperSurgical acquired obp Surgical for approximately $100 million in August 2024, expanding its portfolio of single-use cordless surgical retractors and suction devices.
- In November 2023, the company acquired select assets from Cook Medical, focusing on obstetrics, doppler monitoring, and gynecology surgery markets.
Capital Expenditures
- Capital expenditures for fiscal year 2024 were $421.2 million, resulting in free cash flow of $288.1 million.
- For the nine months ended July 31, 2025, capital expenditures totaled $264.4 million.
- The company expects to generate approximately $2 billion in free cash flow over the next three fiscal years, averaging $650 million annually, supported by reduced capital expenditure as a large investment cycle, particularly for CooperVision's MyDay capacity, concludes.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to COO. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.1% | 21.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 16.7% | 16.7% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.8% | 11.8% | -5.1% |
| 08312025 | COO | Cooper Companies | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 22.5% | 22.5% | -4.6% |
| 12312022 | COO | Cooper Companies | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 16.0% | 14.5% | -7.2% |
| 06302022 | COO | Cooper Companies | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 6.8% | 22.5% | -20.6% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Cooper Companies
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 89.35 |
| Mkt Cap | 70.7 |
| Rev LTM | 12,163 |
| Op Inc LTM | 2,253 |
| FCF LTM | 2,266 |
| FCF 3Y Avg | 1,681 |
| CFO LTM | 2,842 |
| CFO 3Y Avg | 2,218 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.2% |
| Rev Chg 3Y Avg | 6.7% |
| Rev Chg Q | 6.7% |
| QoQ Delta Rev Chg LTM | 1.7% |
| Op Mgn LTM | 19.2% |
| Op Mgn 3Y Avg | 18.3% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 22.2% |
| CFO/Rev 3Y Avg | 19.9% |
| FCF/Rev LTM | 16.9% |
| FCF/Rev 3Y Avg | 14.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 70.7 |
| P/S | 4.0 |
| P/EBIT | 22.7 |
| P/E | 27.9 |
| P/CFO | 20.6 |
| Total Yield | 2.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.2% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.0% |
| 3M Rtn | 15.4% |
| 6M Rtn | 16.6% |
| 12M Rtn | 4.0% |
| 3Y Rtn | 22.2% |
| 1M Excs Rtn | -3.1% |
| 3M Excs Rtn | 10.5% |
| 6M Excs Rtn | 3.7% |
| 12M Excs Rtn | -10.9% |
| 3Y Excs Rtn | -59.1% |
Comparison Analyses
Price Behavior
Price Behavior
| Market Price | $82.57 | |
| Market Cap ($ Bil) | 16.5 | |
| First Trading Date | 12/30/1983 | |
| Distance from 52W High | -17.0% | |
| 50 Days | 200 Days | |
| DMA Price | $75.31 | $74.47 |
| DMA Trend | down | up |
| Distance from DMA | 9.6% | 10.9% |
| 3M | 1YR | |
| Volatility | 29.7% | 36.7% |
| Downside Capture | 13.36 | 81.86 |
| Upside Capture | 108.92 | 58.09 |
| Correlation (SPY) | 28.7% | 42.2% |
COO Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.98 | 0.65 | 0.81 | 0.72 | 0.79 | 0.79 |
| Up Beta | 1.02 | 1.45 | 1.33 | 1.54 | 1.03 | 1.00 |
| Down Beta | 1.24 | 1.11 | 0.66 | 0.59 | 0.66 | 0.61 |
| Up Capture | 190% | 73% | 105% | 53% | 32% | 35% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 10 | 21 | 32 | 69 | 125 | 368 |
| Down Capture | 39% | -13% | 49% | 43% | 89% | 95% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 9 | 20 | 30 | 55 | 122 | 378 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of COO With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| COO | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -10.2% | 16.4% | 19.2% | 71.9% | 8.9% | 6.0% | -10.1% |
| Annualized Volatility | 36.5% | 17.3% | 19.5% | 19.3% | 15.3% | 17.1% | 35.0% |
| Sharpe Ratio | -0.22 | 0.72 | 0.78 | 2.69 | 0.36 | 0.18 | -0.12 |
| Correlation With Other Assets | 48.5% | 42.3% | 9.0% | 9.7% | 47.1% | 14.8% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of COO With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| COO | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -0.8% | 8.6% | 14.9% | 18.7% | 11.7% | 4.8% | 32.7% |
| Annualized Volatility | 28.8% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.7% |
| Sharpe Ratio | 0.00 | 0.41 | 0.70 | 0.97 | 0.51 | 0.17 | 0.60 |
| Correlation With Other Assets | 56.1% | 52.9% | 15.9% | 10.2% | 53.1% | 21.8% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of COO With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| COO | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 9.1% | 9.8% | 14.7% | 14.9% | 6.9% | 5.2% | 69.3% |
| Annualized Volatility | 27.7% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.36 | 0.48 | 0.70 | 0.83 | 0.31 | 0.22 | 0.90 |
| Correlation With Other Assets | 59.8% | 57.7% | 9.7% | 16.5% | 51.6% | 18.1% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 12/4/2025 | 5.7% | 6.6% | |
| 8/27/2025 | -12.9% | -8.2% | -8.8% |
| 5/29/2025 | -14.6% | -11.0% | -11.0% |
| 3/6/2025 | -6.6% | -14.6% | -18.9% |
| 12/5/2024 | -4.4% | -6.3% | -10.2% |
| 8/28/2024 | 11.8% | 12.7% | 16.1% |
| 5/30/2024 | 4.5% | 5.6% | -4.3% |
| 2/29/2024 | 9.2% | 9.1% | 6.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 13 | 12 |
| # Negative | 10 | 11 | 12 |
| Median Positive | 4.4% | 6.5% | 7.3% |
| Median Negative | -3.8% | -7.6% | -10.2% |
| Max Positive | 11.8% | 12.7% | 16.1% |
| Max Negative | -14.6% | -14.6% | -18.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 10312025 | 12052025 | 10-K 10/31/2025 |
| 7312025 | 8282025 | 10-Q 7/31/2025 |
| 4302025 | 5302025 | 10-Q 4/30/2025 |
| 1312025 | 3072025 | 10-Q 1/31/2025 |
| 10312024 | 12062024 | 10-K 10/31/2024 |
| 7312024 | 8292024 | 10-Q 7/31/2024 |
| 4302024 | 5312024 | 10-Q 4/30/2024 |
| 1312024 | 3012024 | 10-Q 1/31/2024 |
| 10312023 | 12082023 | 10-K 10/31/2023 |
| 7312023 | 8312023 | 10-Q 7/31/2023 |
| 4302023 | 6022023 | 10-Q 4/30/2023 |
| 1312023 | 3032023 | 10-Q 1/31/2023 |
| 10312022 | 12092022 | 10-K 10/31/2022 |
| 7312022 | 9012022 | 10-Q 7/31/2022 |
| 4302022 | 6032022 | 10-Q 4/30/2022 |
| 1312022 | 3042022 | 10-Q 1/31/2022 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.